Vendors appeal Spanish fines for alleged price fixing

Article

Four companies that manufacture and supply radiopharmaceutical products are appealing a decision by Spanish authorities that they were guilty of price fixing sales to a Madrid hospital. If the appeal fails, they face fines totaling €1 million ($1.3 million).

Four companies that manufacture and supply radiopharmaceutical products are appealing a decision by Spanish authorities that they were guilty of price fixing sales to a Madrid hospital. If the appeal fails, they face fines totaling €1 million ($1.3 million).

The case against the Spanish subsidiaries of Amersham Health (now part of GE Healthcare), Tyco Healthcare, Schering, and Madrid-based Nucliber was brought by Madrid's Hospital Universitario Gregorio Marañón. The hospital claimed in submissions to Spain's competition defense tribunal (TDC) that the four had fixed the prices of their radiopharmaceuticals while competing as part of a request for proposal issued by the hospital in January 2001.

Although TDC judges found no evidence of direct collusion among the companies, they ruled that there was sufficient evidence to suggest that some sort of agreement had been made. The TDC concluded that pricing similarities in tenders at levels far above the hospital's ceiling price could not be sheer coincidence. In response, they levied a €250,000 ($335,000) fine on each defendant.

DI SCAN has been told that all four companies are in the process of appealing the decision, which was made in August 2004. The appeals have been lodged independently.

"Schering SA has already announced the intention to appeal the ruling. It has also declared that there was no price fixing with other companies," a spokesperson for Schering AG said.

The other companies are taking the same hard-line stance.

"GE Healthcare does not accept the ruling and the conclusions reached," a GE spokesperson said.

Appeals against the judgment and the fine, which is on hold pending further action by the four companies, will be considered by Spanish authorities in 2005. Information about the case is subject to reporting restrictions. DI SCAN was unable to confirm specific details of the tenders subject to legal scrutiny, including the radiopharmaceutical products or prices offered to Hospital Universitario Gregorio Marañón.

"We can make no further comment at the moment because this matter is confidential and because there is nothing to say other than we strongly disagree with the decision and we have appealed," a Tyco Healthcare spokesperson said.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.